Summary & Overview
CPT 85461: Postpartum Fetomaternal Rosette Test for Rh-Negative Patients
CPT code 85461 identifies a laboratory test that detects fetal red blood cells in the maternal bloodstream after delivery using the rosette technique. Clinically, the test is used for Rh negative postpartum patients to quantify or detect fetomaternal hemorrhage risk and guide subsequent immunohematology decisions. Nationally, this code supports essential postpartum care pathways and transfusion/immunoprophylaxis planning.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The review addresses how this laboratory service is billed and reimbursed across major commercial and public payers and summarizes clinical context relevant to postpartum Rh management.
Readers will learn what the code represents, typical sites of service where the test is performed, and the clinical rationale for performing the assay. The publication also provides benchmarks and coverage patterns where available, notes on common billing modifiers, and policy considerations that affect laboratory use of the code. Data not available in the input is explicitly identified where applicable.
Billing Code Overview
CPT code 85461 describes a laboratory procedure in which a lab analyst evaluates whole blood from a post–delivery Rh negative patient to determine the presence of fetal cells mixed with maternal blood using the rosette technique. This test is used to assess fetomaternal hemorrhage following delivery.
Service Type: Laboratory test to detect fetal red blood cells in maternal circulation using the rosette method.
Typical Site of Service: Hospital laboratory or independent clinical laboratory performing postpartum blood analysis.
Clinical & Coding Specifications
Clinical Context
A postpartum maternal blood specimen is submitted to the hospital laboratory after delivery of an Rh-positive neonate to an Rh-negative mother. The laboratory technologist receives a whole blood sample, documents maternal identifiers and delivery time, and performs the rosette screen per protocol to detect fetal (D-positive) red blood cells in maternal circulation. The workflow includes: sample accessioning, mixing of anti-D reagent with patient red cells, application of indicator red cells to detect rosette formation, microscopic evaluation, and reporting of results. A positive rosette screen triggers confirmatory quantification (e.g., Kleihauer-Betke or flow cytometry) to determine volume of fetomaternal hemorrhage and guide further administration of immune globulin. Typical site of service is the hospital clinical laboratory or outpatient laboratory associated with obstetrics services. Typical patient scenario: a 28-year-old G1P1 Rh-negative woman delivers at term; cord blood confirms an Rh-positive neonate; a post-delivery whole blood specimen is sent for rosette screening to assess for fetomaternal hemorrhage and need for additional anti-D immune globulin dosing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard claim processing | Use when no specific circumstance modifier applies. |
11 |